{"filing":{"accession_number":"0001213900-26-091896","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-08-20","report_date":"2026-08-20","primary_document":"ea0302833-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026091896/ea0302833-6k_radiopharm.htm"},"events":[{"id":28710,"run_id":26272,"accession_number":"0001213900-26-091896","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This announcement discloses a positive Data Safety and Monitoring Committee (DSMC) recommendation to advance the Phase 1 HEAT clinical trial of 177Lu-RAD202 to Cohort 4 at a higher dose level (180mCi) in HER2-positive advanced solid tumors. This represents a material clinical development milestone for a clinical-stage biopharmaceutical company's lead therapeutic candidate, demonstrating favorable safety and supporting progression to the next dose level. While not a discrete event type like M\u0026A or exec change, this is a significant operational/clinical milestone that would affect a reasonable investor's assessment of the company's pipeline progress and de-risking of its most promising asset.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-08-20","form":"6-K","submitted_at":null,"items":[{"id":30748,"accession_number":"0001213900-26-091896","item_number":"EX-99.1","item_title":"ea030283301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses a positive Data Safety and Monitoring Committee (DSMC) recommendation to advance the Phase 1 HEAT clinical trial of 177Lu-RAD202 to Cohort 4 at a higher dose level (180mCi) in HER2-positive advanced solid tumors. This represents a material clinical development milestone for a clinical-stage biopharmaceutical company's lead therapeutic candidate, demonstrating favorable safety and supporting progression to the next dose level. While not a discrete event type like M\u0026A or exec change, this is a significant operational/clinical milestone that would affect a reasonable investor's assessment of the company's pipeline progress and de-risking of its most promising asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T12:00:41.964052+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30748,"accession_number":"0001213900-26-091896","item_number":"EX-99.1","item_title":"ea030283301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses a positive Data Safety and Monitoring Committee (DSMC) recommendation to advance the Phase 1 HEAT clinical trial of 177Lu-RAD202 to Cohort 4 at a higher dose level (180mCi) in HER2-positive advanced solid tumors. This represents a material clinical development milestone for a clinical-stage biopharmaceutical company's lead therapeutic candidate, demonstrating favorable safety and supporting progression to the next dose level. While not a discrete event type like M\u0026A or exec change, this is a significant operational/clinical milestone that would affect a reasonable investor's assessment of the company's pipeline progress and de-risking of its most promising asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T12:00:41.964052+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-08-20"}]}